Trials / Completed
CompletedNCT00554606
Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis
A 54-week, Phase II, Multi-center, Open-label Extension Study to Evaluate the Efficacy, Safety and Tolerability of ACZ885 (Anti-interleukin-1B Monoclonal Antibody) in Patients With Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 115 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density, and long term maintenance of health-related quality of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Canakinumab | Canakinumab |
Timeline
- Start date
- 2007-10-11
- Primary completion
- 2009-08-13
- Completion
- 2009-08-13
- First posted
- 2007-11-07
- Last updated
- 2021-07-09
- Results posted
- 2021-07-09
Locations
51 sites across 9 countries: United States, Belgium, Germany, Italy, Netherlands, Russia, Spain, Switzerland, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00554606. Inclusion in this directory is not an endorsement.